Form 4: Phillip Frost and Frost Gamma Investments Trust Report Changes in OPKO Health Beneficial Ownership

Phillip Frost, along with Frost Gamma Investments Trust, reports transactions involving OPKO Health's convertible notes and common stock.

Summary

• Phillip Frost, as CEO & Chairman, Director, and 10% Owner of OPKO Health, Inc., along with Frost Gamma Investments Trust, filed a Form 4 detailing changes in beneficial ownership.
• The transactions involve the acquisition of 3.75% Convertible Notes due 2029 and common stock.
• On March 3, 2025, $1,000,000 of the 3.75% Convertible Notes due 2029 were purchased.
• The conversion price of the notes is $1.15, and they are convertible into common stock after September 15, 2028, and before January 15, 2029.
• Following the reported transactions, Frost Gamma Investments Trust beneficially owns $38,308,000 in 3.75% Convertible Notes due 2029.
• The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee.
• Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust.
• Dr. Frost is one of two limited partners of Frost Gamma L.P.
• The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation.
• Dr. Frost is also the sole shareholder of Frost-Nevada Corporation.
• The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions and ownership details.

Future Outlook

The document does not contain specific forward-looking statements regarding OPKO Health's future performance, but it outlines the terms and conditions of the convertible notes, which could impact the company's capital structure in the future.

Management Comments

• The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and major shareholders. This filing indicates changes in Phillip Frost's and Frost Gamma Investments Trust's holdings in OPKO Health, which is relevant to investors monitoring insider activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in compliance with SEC regulations.
• The terms of the convertible notes, such as the interest rate and conversion price, can be compared to similar debt instruments issued by other companies in the healthcare sector to assess their relative attractiveness.

Stakeholder Impact

• The transactions reported in the Form 4 may influence investor sentiment and potentially impact the share price of OPKO Health.
• The conversion of the notes could dilute existing shareholders' equity if a significant number of notes are converted into common stock.

Key Dates